Ares Capital Corp. (0HHP)
London Exchange · UK · prices in USD · close of 19 Oct 2026
Key indicators
| Last close | USD 18.44 |
|---|---|
| 52-week range | 16.55 – 19.89 |
| Return, 1 month / 3 months | −5.0% / −0.4% |
| Return, 1 year / 3 years | +7.7% / +26.3% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 40 |
| Volatility (1 year) | 19.0% |
| Worst drawdown (1 year) | -14.6% |
| Average daily value traded | 0.33M USD |
| Dividend yield | 10.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Ares Capital Corporation is a business development company that supplies financing to middle-market businesses, mostly in the United States. It lends through senior secured loans and mezzanine debt and also takes equity stakes in the companies it backs. Its borrowers are private firms seeking capital for growth, acquisitions or refinancing, and it works alongside private equity sponsors. The company is based in New York and is managed by an affiliate of Ares Management.
On this site Ares Capital Corp. appears as a stock on the London Exchange (UK), code 0HHP, with prices in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Ares Capital Corp. (0HHP) trades on the London Exchange in UK. It last closed at USD 18.44 on 19 October 2026.
Its price-based Market X-Ray is 67 out of 100 (a fair price profile), ranking 762 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 7.7% and over the last three months it fell 0.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 64 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 0.5% | ||
| From 52-week high | -6.9% | ||
| Momentum | 56 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -0.4% | ||
| 6-month return | 2.7% | ||
| 12-month return, skipping the last month | 13.4% | ||
| Stability (higher is calmer) | 88 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 19.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -14.6% | ||
| Liquidity | 41 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.33M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 91 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 10.4% | ||
| Years with dividends | 6 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Income: Dividend is high and has been paid regularly.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −1.1% |
|---|---|
| 1 month | −5.0% |
| 3 months | −0.4% |
| 6 months | +2.7% |
| 1 year | +7.7% |
| 3 years | +26.3% |
| 5 years | – |
Signals
| 50-day / 200-day average | 19.22 / 18.35 |
|---|---|
| Golden / death cross (60 days) | Golden, 53 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.37 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 Sep 2026 | USD 0.4800 |
| 12 Jun 2026 | USD 0.4800 |
| 12 Mar 2026 | USD 0.4800 |
| 15 Dec 2025 | USD 0.4800 |
| 15 Sep 2025 | USD 0.4800 |
| 13 Jun 2025 | USD 0.4800 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.